Abstract 590P
Background
Colorectal cancer (CRC) CRC with peritoneal metastasis (PM) obtain poor prognosis. Peritoneal Cancer Index (PCI) is used to evaluate the PM extent and selection of Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). However, PCI score assessed before surgery is not precise.We have developed a novel AI framework of DeAF (Decoupling feature alignment and fusion) to aid the selection and predict completeness of CRS in PM.
Methods
185 CRC patients with PM recruited from four tertiary hospitals were enrolled. The internal patient cohort was subsequently stratified into training and validation cohorts, comprising 84 and 30 individuals, respectively. Deep learning was used to train the DeAF model of Simsam algorithms by contrast CT images and then cooperate with clinicopathological parameters to increase the performance. The performance was evaluated by accuracy, sensitivity, specificity, and AUC by ROC in the internal and external validation cohorts.
Results
The AI model demonstrated a robust ability to predict the completeness of CRS with AUC of 0.9 in internal validation cohort. The model can predict whether patients are suitable for CRS. It can differentiate patients who would benefit from CRS. The model also showed high predictive performance of CRS completeness in external validation cohorts with AUC values of 0.906, 0.960, and 0.933, respectively (rounded to three decimal places).
Conclusions
The novel DeAF framework can aid surgeons to select proper patients for CRS and predict the completeness of CRS. The model can change surgical decision-making and provide potential benefits for patients with PM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
458P - Patterns of care and clinical outcomes of patients with glioblastoma in the United States from 2005-2020: A real-world analysis
Presenter: Diya Jayram
Session: Poster session 16
459P - Association of tumor treating fields device usage with survival in newly diagnosed GBM: A real-world analysis of patients in the US
Presenter: Jennifer Connelly
Session: Poster session 16
460P - Exploring the efficacy and optimal timing of tumor treating fields in newly diagnosed glioblastoma: A real-world study
Presenter: Zelei Dai
Session: Poster session 16
461P - Effectiveness of dabrafenib-trametinib and larotrectinib in adult recurrent glioblastoma patients: A real-life cohort analysis from 3 Italian centers
Presenter: Marta Padovan
Session: Poster session 16
462P - Regorafenib for relapsed glioblastoma: Retrospective real-world analysis of a single Institution experience
Presenter: Giulia Rovesti
Session: Poster session 16
463P - Real-world outcomes of patients with non-small cell lung cancer with and without intracranial metastatic disease: A retrospective cohort analysis
Presenter: Madison Sherman
Session: Poster session 16
465P - Surgical intervention association with the development of subsequent dissemination in childhood diffuse intrinsic pontine gliomas (DIPG)
Presenter: Shoaib Bashir
Session: Poster session 16
Resources:
Abstract
466P - Re-irradiation therapy for pediatric brainstem tumours: 20 years of clinical experience
Presenter: Olga Regentova
Session: Poster session 16
Resources:
Abstract
467P - Temozolomide potentially postpones the development of subsequent metastases in pediatric diffuse intrinsic pontine glioma (DIPG) patients
Presenter: Shoaib Bashir
Session: Poster session 16
Resources:
Abstract